Renaissance Technologies LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Renaissance Technologies LLC grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,706,116 shares of the biopharmaceutical company’s stock after buying an additional 180,100 shares during the quarter. Renaissance Technologies LLC’s holdings in Catalyst Pharmaceuticals were worth $56,477,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $27,000. Farther Finance Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. KBC Group NV lifted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $134,000. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CPRX. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Stephens restated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $22.74 on Thursday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The firm has a 50 day moving average price of $22.68 and a 200 day moving average price of $21.98. The company has a market capitalization of $2.76 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.